MarthaJaneMooreMDMPH

PubMed

• Randomized multicenter phase III study in patients with locally advanced adenocarcinoma of the pancreas: Gemcitabine with or without chemoradiotherapy and with or with...
  Hammel P, Huguet F, Van Laethem J, Goldstein D, Glimelius B, Moore MJ, Chibaudel B, Bonnetain F, Louvet C> ;J. Clin. Oncol.. 2011-05-20
• Screening for pancreatic cancer in a high-risk cohort: A 7-year experience.
  Al-Sukhni W, Borgida A, Rothenmund H, Holter S, Wilson S, Moore MJ, Narod S, Jhaveri K, Haider MA, Gallinger S> ;J. Clin. Oncol.. 2011-05-20
• A multinational, randomized phase III study of bevacizumab (Bev) with FOLFOX4 or XELOX versus FOLFOX4 alone as adjuvant treatment for colon cancer (CC): Subgroup analy...
  Andre T, Van Cutsem E, Schmoll H, Tabernero J, Clarke S, Moore MJ, Cunningham D, Cartwright TH, Hecht JR, Rivera F, Im S, Bodoky G, Salazar R, Maindrault-Goebel F, Shm...> ;J. Clin. Oncol.. 2011-05-20
• AVANT: Results from a randomized, three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX4 versus FOLFOX4 alone as adjuvant trea...
  De Gramont A, Van Cutsem E, Tabernero J, Moore MJ, Cunningham D, Rivera F, Im S, Makrutzki M, Shang A, Hoff PM> ;J. Clin. Oncol.. 2011-02-01
• A review of the patterns of docetaxel use for hormone refractory prostate cancer (HRPC) at the Princess Margaret Hospital.
  Chin SN, Wang L, Lau A, Moore M, Sridhar SS> ;J. Clin. Oncol.. 2009-05-20
• High epiregulin (EREG) gene expression plus K-ras wild-type (WT) status as predictors of cetuximab benefit in the treatment of advanced colorectal cancer (ACRC): Resul...
  Jonker DJ, Karapetis C, Harbison C, O'Callaghan CJ, Tu D, Simes RJ, Xu L, Moore MJ, Zalcberg JR, Khambata-Ford S> ;J. Clin. Oncol.. 2009-05-20
• Randomized phase II trial of capecitabine versus capecitabine, low molecular weight heparin, and prednisone in refractory colorectal carcinoma.
  Mak E, Townsley C, Buckman R, Chen E, Lopez L, Wang L, Moore M, Oza AM> ;J. Clin. Oncol.. 2009-05-20
• Gas bubbles in seals, dolphins, and porpoises entangled and drowned at depth in gillnets.
  Moore, M.J., Bogomolni, A.L., Dennison, S.E., Early, G., Garner, M.M., Hayward, B.A., Lentell, B.J., Rotstein, D.S.> ;Vet Pathol. 2009-05-01
• Investigation of a multimarker approach to the initial assessment of patients with acute chest pain.
  McCann, C.J., Glover, B.M., Menown, I.A., Moore, M.J., McEneny, J., Owens, C.G., Smith, B., Sharpe, P.C., Young, I.S., Adgey, J.A.> ;Adv Ther. 2009-05-01
• A prospective economic analysis of cost-effectiveness of cetuximab for metastatic colorectal cancer patients from the NCIC CTG and AGITG CO.17 trial.
  Mittmann N, Au HJ, Tu D, O'Callaghan CJ, Karapetis CS, Moore MJ, Zalcberg J, Simes J, Evans WK, Jonker DJ> ;J. Clin. Oncol.. 2008-05-20
• A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret hospit...
  Mackenzie, M.J., Saltman, D., Hirte, H., Low, J., Johnson, C., Pond, G., Moore, M.J.> ;Invest New Drugs. 2007 Dec
• A phase I study of axitinib (AG-013736), a potent inhibitor of VEGFRs, in combination with gemcitabine (GEM) in patients (pts) with advanced pancreatic cancer.
  Spano J, Moore M, Kim S, Liau KF, Hee B, Bycott P, Boissaye P, Francis S, Peters D, Rixe O> ;J. Clin. Oncol.. 2006-06-20
• A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first line treatment in hormone refractory prostate cancer (HRPC).
  Sridhar SS, Canil CM, Hotte SJ, Chi K, Ernst S, Pond GR, Dick C, Zwiebel JA, Moore MJ> ;J. Clin. Oncol.. 2006-06-20
• Phase II study of bortezomib in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital [PMH] Phase II Consortium.
  Sridhar SS, Stadler W, Le L, Hedley D, Pond G, Wright J, Vokes E, Thomas S, Moore M> ;J. Clin. Oncol.. 2005-06-01
• Should surveillance be considered the standard of care in stage I seminoma?
  Warde PR, Chung P, Sturgeon J, Panzarella T, Giuliani M, Tew-George B, Jewett M, Bayley A, Moore M, Catton C, Gospodarowicz M> ;J. Clin. Oncol.. 2005-06-01
• A phase II trial of perifosine as second line therapy for advanced pancreatic cancer. A study of the Princess Margaret Hospital [PMH] Phase II Consortium.
  Hedley D, Moore MJ, Hirte H, Siu L, Vincent M, Jonker D, Mwang H, Nagai J, Dancey J> ;J. Clin. Oncol.. 2005-06-01
• A phase II study of triapine in combination with gemcitabine in advanced pancreatic carcinoma: A Princess Margaret Hospital Phase II Consortium Trial.
  Mackenzie MJ, Moore MJ, Saltman D, Zbuk KM, Vandesompele E, Lovell S, Degendorfer P, Johnson C, Siu L, Low J> ;J. Clin. Oncol.. 2005-06-01
• Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group.
  > ;J Clin Oncol. 2005 Jan 20
• Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory pro...
  Ernst, D.S., Tannock, I.F., Winquist, E.W., Venner, P.M., Reyno, L., Moore, M.J., Chi, K., Ding, K., Elliott, C., Parulekar, W.> ;J Clin Oncol. 2003 Sep 1
• The palliative benefit of irinotecan in 5-fluorouracil-refractory colorectal cancer: its prospective evaluation by a Multicenter Canadian Trial.
  Michael, M., Hedley, D., Oza, A., Feld, R., Pintilie, M., Goel, R., Maroun, J., Jolivet, J., Fields, A., Lee, I.M., Moore, M.J.> ;Clin Colorectal Cancer. 2002 Aug
• Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients...
  Holmes FA, O'Shaughnessy JA, Vukelja S, Jones SE, Shogan J, Savin M, Glaspy J, Moore M, Meza L, Wiznitzer I, Neumann TA, Hill LR, Liang BC> ;J. Clin. Oncol.. 2002-02-01
• Join now to see all